openPR Logo
Press release

One "Target" for a Month: Creative Biolabs Features TNFRSF9

07-10-2024 08:20 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Getnews

/ PR Agency: PRChoices
One "Target" for a Month: Creative Biolabs Features TNFRSF9

Creative Biolabs introduces its range of TNFRSF9-related antibody reagents.
New York, USA - July 10, 2024 - The growing interest in TNFRSF9 (also known as CD137, 4-1BB) stems from its role as a co-stimulatory receptor on T cells, which can enhance immune responses against tumors. Research has shown that activating TNFRSF9 can significantly boost the efficacy of cancer immunotherapies. To synchronize with recent industry news highlighting the potential of TNFRSF9-targeted therapies to overcome the limitations of existing treatments and deliver durable anti-tumor responses, Creative Biolabs specifies their anti-TNFRSF9 engineered antibodies [https://www.creativebiolabs.net/symbolsearch_TNFRSF9_2.htm] in the monthly briefing.

Image: https://www.getnews.info/uploads/0c59d26f78bf6dd58aafee5bc68d7d8c.jpg

I: Leading in with the Omnipresent Hi-Affi Trademark

"First of all, a short overview of our Hi-Affi Trademark platform to get you a clearer picture of our antibody performance," according to the scientist delivering the presentation, "which is a concert of advanced DNA technologies and powerful cell-free expression systems."

Almost all production work of recombinant antibodies [https://www.creativebiolabs.net/hi-affi-tm-recombinant-antibodies.htm] is run by the Hi-Affi Trademark platform, covering antibodies of different working modalities (blocking, neutralizing, etc.), antibodies against divergent targets (epitope-specific, mRNA encoded, etc.), and antibodies originated from different species (chicken, rabbit, etc.), with which the yielding reagents will be validated to have over 98% purity, high affinity, and reproducibility.

II: Catalog presentation

The scientist revealed a list of their research-use-only antibodies that are readily available for global delivery, and announced that the list is growing to cover more isotypes and more validated applications.

* Rat Anti-TNFRSF9 Recombinant Antibody

* Recombinant Mouse Anti-Human TNFRSF9 Antibody

* Hamster Anti-TNFRSF9 Recombinant Antibody

* Rat Anti-TNFRSF9 Recombinant Antibody

* Rat Anti-TNFRSF9 Recombinant Antibody

* Human Anti-TNFRSF9 Recombinant Antibody

* Human Anti-TNFRSF9 Recombinant Antibody

III: Case study: urelumab-a therapeutic breakthrough

Furthermore, a candidate that had received its final clinical results not a while ago was discussed-urelumab, an agonistic antibody targeting 4-1BB, making it a valuable tool in the fight against cancer. Two studies that evaluated urelumab in combination with cetuximab or nivolumab in patients with select, advanced solid tumors were reported in the paper.

"For relevant studies, we have anti-human 4-1BB recombinant antibodies [https://www.creativebiolabs.net/Anti-Human-4-1BB-Therapeutic-Antibody-Urelumab-13548.htm]," the scientist added, "which have been validated to be positive against native human antigen. Tested data are provided on the product page to help researchers know more about how they work in specific assays, like WB and ELISA."

IV: Outlook

Creative Biolabs prides itself on its commitment to innovation and collaboration and is poised to play a pivotal role in advancing TNFRSF9-targeted therapies.

"As the research community continues to explore the full potential of such critical factors in immunotherapy, we remain dedicated to driving scientific progress." The scientist summarized.

For more information about Creative Biolabs' TNFRSF9 antibodies and to explore their comprehensive product offerings, visit https://www.creativebiolabs.net or contact their expert team.

Company Overview

Creative Biolabs is a biotechnology company specializing in antibody development, engineering, and production. With a strong focus on innovation and customer service, Creative Biolabs provides a wide range of high-quality antibody products to support biomedical research and drug development worldwide.
Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email [http://www.universalpressrelease.com/?pr=one-target-for-a-month-creative-biolabs-features-tnfrsf9]
Phone: 1-631-830-6441
Country: United States
Website: https://www.creativebiolabs.net



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release One "Target" for a Month: Creative Biolabs Features TNFRSF9 here

News-ID: 3575212 • Views:

More Releases from Getnews

Cecily Holland Unveils Her Debut Book
Cecily Holland Unveils Her Debut Book "The Daily Pain: My Journey with Anxiety a …
Image: https://www.globalnewslines.com/uploads/2025/12/9ad5867f540cc4a563821d9913d92a69.jpg Cecily Holland is elated to announce the release of her compelling new book, "The Daily Pain: My Journey with Anxiety and Depression through Faith." This emotionally charged memoir guides readers through Cecily's personal battle with anxiety and depression, shedding light on the multifaceted and often misunderstood nature of mental health challenges. Diving deep into her own vulnerabilities, Cecily Holland presents a raw and honest account of her struggles, aiming to
Maico Audiological Services Debuts Fully Redesigned Website to Enhance Hearing Care Access and Patient Engagement
12-13-2025 | Health & Medicine
Getnews
Maico Audiological Services Debuts Fully Redesigned Website to Enhance Hearing C …
Image: https://www.globalnewslines.com/uploads/2025/12/1765571909.jpg Maico Audiological Services [https://maicoaudio.com/] is pleased to announce the launch of its newly redesigned website, created to offer patients a clearer, more modern, and more convenient way to explore hearing care services. The new platform reflects the clinic's long-standing commitment to providing personalized support and improving access to high-quality audiological care throughout Virginia. The updated site features a clean layout and simplified navigation, enabling visitors to learn about the clinic's
New Five Books Collection by Michael J. Henderson: Explores the Crossroads of Power, Faith, Race, and Personal Truth
New Five Books Collection by Michael J. Henderson: Explores the Crossroads of Po …
Image: https://www.globalnewslines.com/uploads/2025/12/1765570702.jpg A powerful new collection of five books by author Michael J Henderson offers readers a bold look at the forces shaping modern life. Through stories rooted in political pressure, spiritual struggle, racial injustice, and the search for identity, Henderson presents a connected body of work that challenges, informs, and inspires. The collection includes I Found Love on a Two-Way Street: Lost It on a Political Highway, How Deep Is Your
Michael J. Henderson Unites Truth, Love, and Resistance in Three Powerful New Books
Michael J. Henderson Unites Truth, Love, and Resistance in Three Powerful New Bo …
Image: https://www.globalnewslines.com/uploads/2025/12/1765570281.jpg Acclaimed author Michael J. Henderson delivers a bold literary trilogy that confronts the world's oldest struggles, power, control, and the human spirit's fight for truth. Through three deeply connected works, America the Great is Falling: The Rise of Morningstar's Empire - The Son of Dawn, The Forbidden Bloom: Married to Tradition, Drawn to Her, and Wake Up, America: The Colonizers Are Coming, Henderson explores how courage, conscience, and compassion

All 5 Releases


More Releases for TNFRSF9

Tumor Necrosis Factor Receptor Superfamily Member 9: North America to Retain its …
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) pipeline Target constitutes close to 35 molecules. Out of which approximately 31 molecules are developed by companies and remaining by the universities/institutes. To evaluate factors influencing Tumor Necrosis Factor Receptor Superfamily Member 9, Market Research Hub (MRH) has included a report titled “Tumor Necrosis Factor Receptor